Pd-L1 Expression and Survival Among Advanced Non–Small Cell Lung Cancer (Nsclc) Patients Treated with Chemotherapy
Steen Sørensen(Aarhus University Hospital), Henrik Hager(Aarhus University Hospital), Peter Meldgaard(Aarhus University Hospital), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marisa Dolled‐Filhart(Fox Chase Cancer Center), Dianna Wu(Memorial Sloan Kettering Cancer Center), Michael Busch-Sørensen(Center for Clinical & Basic Research), Jeanette Bæhr Georgsen(Aarhus University Hospital), Wei Zhou(Broad Institute), Z. Wang(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 6
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|679